[A15-04] Ombitasvir/paritaprevir/ritonavir - Benefit assessment according to §35a Social Code Book V (dossier assessment)
Last updated 04.05.2015
Project no.:
A15-04
Commission:
Commission awarded on 21.01.2015 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Immune system and infections
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A15-21 | Dasabuvir / ombitasvir/paritaprevir/ritonavir (Addendum to Commissions A15-03 and A15-04) | Commission completed |
Federal Joint Committee (G-BA)
2015-07-16 A G-BA decision was published.